Pfizer stops sale of chil­dren’s Prevnar vac­cine in China

The China Post - - LIFE -

Amer­i­can phar­ma­ceu­ti­cal gi­ant Pfizer has stopped sell­ing one of its lu­cra­tive vac­cines for chil­dren in China, the com­pany said.

Pfizer gave no ex­pla­na­tion for stop­ping its sales of the Prevnar vac­cine, which helps pre­vent in­fec­tions such as pneu­mo­nia, which killed an es­ti­mated 935,000 chil­dren un­der the age of five glob­ally in 2013, ac­cord­ing to the World Health Or­ga­ni­za­tion.

"Based on a care­ful as­sess­ment of this sit­u­a­tion, we have de­cided to cease our Vac­cines com­mer­cial op­er­a­tions in China at this time, ef­fec­tive im­me­di­ately," a spokes­woman said in an email Thurs­day, adding that the drug's im­port li­cense had ex­pired.

Pfizer an­tic­i­pates a short­age of Prevnar in China be­fore the sale of a new vac­cine can begin.

Prevnar vac­cines gen­er­ated US$4.5 bil­lion in rev­enue last year for Pfizer. They are the sec­ond largest con­trib­u­tor to the com­pany's rev­enues, ac­cord­ing to Pfizer's an­nual re­port.

The spokes­woman said that the other ac­tiv­i­ties of the com­pany, which em­ploys about 9,000 peo­ple in China, were not af­fected. China is one of Pfizer's largest mar­kets af­ter the U. S. and Canada.

About 200 po­si­tions at the com­pany will be af­fected by the end of the vac­cine sale.

The set­back comes as phar­ma­ceu­ti­cal com­pa­nies have strug­gled to gain Chi­nese au­thor­i­ties' ap­proval for many of their drugs.

Pfizer said it is in talks with Chi­nese reg­u­la­tors to reg­is­ter and pro­vide an im­proved vac­cine "as soon as pos­si­ble."

Newspapers in English

Newspapers from Taiwan

© PressReader. All rights reserved.